Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522267

Comprehensive Epidemiology, Acute Care, Operative Intervention, and Nursing Management of Cavernous Sinus Thrombosis

Ibrahim Ataa Alaraj Alshehri [1], Falah Atallah F Alhomaidani [2], Ghazi Farhan Aladuhum Aleinziu [3], Mohammed Radhi M Alanazi [4], Hamdan Malaa Hamdan Alanazi [5], Mansour Faraj Alanazi [6], Fahad Ahmed Aljumaiah [7], Entesar Bakr Takroni [8], Yahya Mousa Mohammed Sulayyi [9], Muteb Mohsen H [10], Hamzah Saleem Alamri [11]

(1) Saudi Red Crescent Authority, Al-Jouf, Saudi Arabia,
(2) Red Crescent Authority East Unaizah Center Qassim , Saudi Arabia,
(3) Red Crescent Authority , Saudi Arabia,
(4) Saudi Red Crescent Authority, Saudi Arabia,
(5) Saudi Red Crescent Authority Arar City Northern Borders, Saudi Arabia,
(6) Red Crissint , Ministry of Health, Saudi Arabia,
(7) King Faisl Hospital Alahsa, Ministry of Health, Saudi Arabia,
(8) Bahra Phc, Ministry of Health, Saudi Arabia,
(9) Al-Madha Genaral Hospital-Asir, Ministry of Health, Saudi Arabia,
(10) Ministry Of National Guard, Saudi Arabia,
(11) Eradah Complex And Mental Health. - Eradah Services-Jeddah, Ministry of Health, Saudi Arabia

Abstract

Background: Cavernous Sinus Thrombosis (CST) is a rare, life-threatening condition characterized by thrombotic occlusion of the cavernous sinus, a critical venous plexus at the skull base. It most commonly arises from the septic spread of infections originating in the face, sinuses, or orbits. Despite its rarity, CST carries a high risk of severe morbidity and mortality due to its proximity to crucial neurovascular structures, including cranial nerves and the internal carotid artery.

Aim: This article provides a comprehensive review of CST, aiming to synthesize current knowledge on its epidemiology, pathophysiology, clinical presentation, diagnostic evaluation, and evidence-based management strategies to improve patient outcomes.

Methods: The study is a detailed narrative review, consolidating evidence from clinical studies, case series, and expert guidelines. It covers the anatomical basis, risk factors, microbiological etiology, and systematic approaches to diagnosis and treatment.

Results: CST typically presents with fever, severe headache, periorbital edema, chemosis, and ophthalmoplegia. Diagnosis is confirmed via contrast-enhanced MRI or CT venography. Management is multifaceted and requires immediate, broad-spectrum intravenous antibiotics, often combined with anticoagulation to prevent thrombus propagation. Surgical intervention may be necessary to address the primary source of infection. While modern management has significantly reduced mortality from historical rates of >80% to approximately 8-13%, long-term sequelae such as visual loss and persistent cranial nerve palsies remain common.

Conclusion: Successful outcomes depend on early recognition, rapid neuroimaging, and aggressive, multidisciplinary management involving antimicrobial therapy, anticoagulation, and surgical source control.

Keywords: Cavernous Sinus Thrombosis, Septic Thrombosis, Ophthalmoplegia, Anticoagulation, Cranial Neuropathy, Intracranial Infection

Introduction

Cavernous sinus thrombosis (CST) is an uncommon, yet highly dangerous neurovascular condition characterized by thrombotic obstruction within the cavernous sinus, a critical venous plexus that drains facial, orbital, and intracranial structures. Although rare, CST carries a substantial risk of morbidity and mortality due to its proximity to essential neurovascular structures, including cranial nerves III, IV, V1, V2, and VI, as well as the internal carotid artery. The majority of cases arise from septic etiologies, most commonly as complications of localized infections such as facial cellulitis, paranasal sinusitis, orbital cellulitis, pharyngitis, or otitis, where bacterial pathogens—particularly *Staphylococcus aureus* and anaerobic organisms—extend through venous pathways to the cavernous sinus [1]. However, aseptic CST can also occur

*Corresponding author e-mail: Jufey100@gmail.com (Ibrahim Ataa Alaraj alshehri).

Receive Date: 31 October 2025, Revise Date: 22 November 2025, Accept Date: 24 November 2025

following trauma, neurosurgical or sinus procedures, or in individuals with underlying prothrombotic disorders, highlighting its multifactorial pathogenesis and diverse clinical presentations [2]. Clinically, CST often manifests with a constellation of rapidly progressive symptoms, including fever, severe headache, periorbital swelling, chemosis, and ophthalmoplegia due to cranial nerve dysfunction. These signs reflect both inflammatory propagation and mechanical compromise within the cavernous sinus, with contralateral involvement developing in many patients due to the interconnecting venous channels [3]. Early recognition of this pattern is crucial, as delays in diagnosis may result in catastrophic neurological consequences. Despite advancements in neuroimaging, antimicrobial therapy, and supportive care, CST continues to be associated with serious complications, including visual loss, persistent diplopia, cerebral infarction, and intracranial extension of infection [4]. Management typically requires a combination of prompt empiric broad-spectrum antibiotics, anticoagulation where appropriate, and multidisciplinary critical care support. Even with timely intervention, long-term sequelae remain common, reflecting the severity of the inflammatory and thrombotic processes involved [5]. Therefore, heightened clinical vigilance, rapid diagnostic evaluation, and early coordinated management are essential components of improving patient outcomes in this life-threatening condition [1][2][3][4][5].

Etiology

Cavernous sinus thrombosis (CST) arises from a diverse range of infectious and noninfectious mechanisms, though septic etiologies remain the most frequent and clinically significant. The cavernous sinus receives venous drainage from the midface, paranasal sinuses, orbit, and deep cerebral venous system, creating a pathway through which localized infections can rapidly extend into the intracranial venous network. Septic CST most commonly develops from facial infections originating within the highly vascular “danger triangle” of the face, spanning from the corners of the mouth to the nasal bridge. This region contains valveless venous channels that permit retrograde spread of pathogens into the cavernous sinus. Infections such as facial cellulitis, furuncles, abscesses, or infected wounds can therefore progress to CST if inadequately treated or if host defenses are compromised. Paranasal sinus infections, particularly sphenoid and ethmoid sinusitis, represent another major source of septic CST due to their direct anatomical continuity with the cavernous sinus and the thin bony boundaries separating these structures [6]. Middle ear infections, mastoiditis, orbital cellulitis, dental infections, maxillofacial surgery, and even posterior superior alveolar nerve blocks may also provide routes for bacterial dissemination into the cavernous sinus. Although less common, aseptic CST presents an important subset of cases arising from noninfectious factors. Head trauma, craniofacial fractures, neurosurgical or sinus procedures, and pregnancy can precipitate aseptic CST through endothelial injury or hypercoagulability. These mechanisms often involve localized thrombosis secondary to vascular disruption rather than infectious invasion. Pregnant and postpartum women may experience CST due to pregnancy-induced hypercoagulability, venous stasis, or dehydration, further highlighting the multifactorial nature of the disorder [6].



Fig. 1: Cavernous sinus thrombosis (CST).

A wide spectrum of pathogens is implicated in CST, with bacterial agents dominating clinical presentations. *Staphylococcus aureus*, including methicillin-resistant strains, accounts for roughly two-thirds of septic cases. *Streptococcus* species contribute to nearly 20% of infections, while *Streptococcus pneumoniae* appears less frequently, around 5% of cases. Gram-negative organisms—including *Proteus*, *Pseudomonas*, *Haemophilus*, *Fusobacterium*, and *Bacteroides*—also contribute to CST, reflecting the polymicrobial nature of some facial or sinus infections. Anaerobes such as *Actinomyces* and *Fusobacterium* further complicate treatment due to their aggressive tissue invasiveness and potential to spread along fascial planes. Fungal CST, while rare, poses a severe threat in immunocompromised individuals. *Aspergillus* and *Mucor* species are the predominant culprits, often associated with uncontrolled diabetes mellitus or severe immunosuppression, leading to fulminant angioinvasive disease and rapidly progressive thrombosis. Parasitic causes such as toxoplasmosis, malaria, and trichinosis are rare but reported, typically in individuals with significant immunodeficiency. Viral etiologies—including herpes simplex virus, cytomegalovirus, measles, hepatitis viruses, and HIV—can induce cavernous sinus involvement through direct inflammation or secondary hypercoagulability.

Cavernous Sinus Thrombosis Risk Factors

The likelihood of developing CST is heavily influenced by both host-specific and environmental factors. Immunosuppression represents a major contributor, predisposing individuals to severe infections with increased risk of intracranial spread. Poorly controlled diabetes mellitus, chronic steroid use, chemotherapy, hematologic malignancies, and advanced HIV infection impair immune responses and facilitate pathogen proliferation [7]. The most common and significant risk factors remain facial infections, acute sinusitis, and periorbital infections, reflecting the anatomical connectivity and ease of pathogen migration toward the cavernous sinus. Thrombophilia, both inherited and acquired, also plays a pivotal role in CST pathogenesis. Inherited thrombophilic disorders associated with CST include factor V Leiden mutation, prothrombin G20210A mutation, protein C and protein S deficiencies, antithrombin III deficiency, and elevated factor VIII levels. These genetic abnormalities contribute to hypercoagulability, increasing the propensity for thrombosis within the cavernous sinus even in the absence of severe infection. Women who are pregnant, postpartum, or using oral contraceptives or hormone replacement therapy face disproportionately higher CST risk due to hormonally driven increases in coagulability and venous stasis [8]. Acquired prothrombotic conditions also contribute substantially. Antiphospholipid antibody syndrome, hyperhomocysteinemia, heparin-induced thrombocytopenia, and obesity all promote thrombosis under specific conditions. Systemic illnesses such as nephrotic syndrome, severe dehydration associated with hyperosmolar nonketotic states, and sickle cell disease further elevate CST risk by altering blood viscosity, promoting stasis, and damaging endothelial integrity [9][10]. Together, these factors illustrate that CST is a multifactorial condition resulting from complex interactions among infectious agents, vascular anatomy, host immunity, and coagulation abnormalities.

Epidemiology

Cavernous sinus thrombosis (CST) is an exceptionally rare but clinically significant condition, and its precise incidence is challenging to determine due to its low frequency and frequent underdiagnosis. It is generally understood within the broader category of cerebral venous and sinus thrombosis (CVST), of which CST represents only about 1% to 4% of cases. Given that the annual global incidence of CVST is estimated at roughly 2 to 4 cases per million individuals per year, the derived annual incidence of CST is correspondingly lower, ranging between approximately 0.2 and 1.6 per 100,000 people per year [11]. This rarity contributes to difficulties in establishing accurate epidemiologic trends, particularly since many reported cases originate from isolated clinical observations or small case series rather than large population-based studies. Unlike CVST as a whole, which exhibits a well-established female predominance with a ratio of approximately 3:1—largely attributed to sex-specific risk factors such as pregnancy, the puerperium, and oral contraceptive use—such gender bias does not clearly apply to CST. In fact, several studies suggest a mild male predominance. Weerasinghe and Lueck, in their evaluation of 88 adult septic CST cases, reported a male-to-female ratio of 2:1, indicating that CST may follow a distinct epidemiologic pattern compared with other forms of CVST [12]. Additional smaller series, such as those reported by Thatai et al. and Smith et al., have echoed similar findings, each showing a modest male predominance in their cohorts. These variations may reflect differing exposure risks, environmental factors, or underlying etiologies rather than true biological predisposition, but the limited sample sizes preclude definitive conclusions. Age-related differences in CST incidence also add complexity to its epidemiologic profile. Historically, CVST—including CST—was believed to be more common in neonates and children than in adults, potentially related to higher rates of systemic infections, otitis media, mastoiditis, and dehydration in younger populations. However, the widespread use of antibiotics, improved vaccination coverage, and enhanced public health measures may have contributed to a decline in septic CST among children. This trend parallels the broader reduction in severe infectious complications affecting the head and neck in pediatric populations. Nevertheless, because CST often arises from contiguous facial, sinus, or orbital infections, clinicians must remain vigilant in high-risk pediatric groups, particularly in settings where access to antibiotics or vaccination may be limited. Overall, CST appears to be decreasing in both incidence and mortality due to advances in early diagnosis, imaging, and aggressive antimicrobial therapy. Before the antibiotic era, mortality exceeded 80%, but modern management has significantly reduced fatality rates, although morbidity remains substantial. As such, CST continues to be a rare but serious clinical entity that necessitates rapid recognition and treatment, and its epidemiologic profile reflects an interplay between infectious disease control, medical advancements, and demographic factors.

Pathophysiology

Anatomic Structures

The pathophysiology of cavernous sinus thrombosis (CST) is closely linked to the highly complex anatomical relationships of the cavernous sinus and its draining venous network. The cavernous sinuses are paired, trabeculated venous channels situated on either side of the sella turcica, superior and lateral to the sphenoid sinus and flanking the body of the sphenoid bone. Anteriorly, each cavernous sinus is bounded by the superior orbital fissure, while posteriorly it extends toward the petrous apex of the temporal bone. Within these confines, multiple leaflets of dura mater create interconnected cavernous spaces that are filled with low-pressure venous blood. Venous inflow to the cavernous sinus arises primarily from the superior and inferior ophthalmic veins, which drain the orbit and periorbital structures, as well as from superficial cortical veins and veins of the midface. The sinus then drains posteriorly into the superior and inferior petrosal sinuses, which in turn communicate with the basilar venous plexus and internal jugular veins. Critically, venous channels in this region, including facial, ophthalmic, and emissary veins, are valveless, allowing bidirectional flow and facilitating retrograde spread of infection and thrombus. The cavernous sinus has been aptly termed an "anatomic jewel box" because it encases or closely borders several vital neurovascular structures. Traversing the sinus medially are the horizontal (cavernous) segment of the internal carotid artery, its surrounding sympathetic plexus, and the abducens nerve (cranial nerve VI). Within the lateral dural wall of the sinus course the oculomotor nerve (III), the trochlear nerve (IV), and the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve. This intimate anatomic relationship explains why even modest degrees of inflammatory edema, thrombosis, or mass effect within the cavernous sinus can rapidly produce ophthalmoplegia, sensory disturbances, and vascular complications.

Pathophysiologic Mechanisms of Thrombosis

Cavernous sinus thrombosis most often results from septic processes that originate in adjacent or draining territories, although aseptic thrombotic mechanisms may occur in the context of trauma, surgery, or systemic hypercoagulability. Septic CST arises classically from infections that propagate via valveless facial and ophthalmic veins or from directly contiguous structures. Common sources include acute or chronic sinusitis—particularly of the sphenoid and ethmoid sinuses—facial cellulitis or abscesses within the so-called "danger" or nasolabial triangle of the face, as well as periorbital and orbital cellulitis. Infections of the upper aerodigestive tract, such as pharyngitis and tonsillitis, and otologic or mastoid disease including otitis media and mastoiditis, may similarly extend through regional venous pathways to the cavernous sinus. Dental infections, maxillofacial surgical procedures, and even posterior superior alveolar nerve blocks can introduce pathogens into the pterygoid venous plexus, which communicates with the cavernous sinus and thereby provides another route for septic thrombus formation.[13] At the microvascular level, the pathogenesis of CST reflects a combination of infectious embolization, endothelial injury, and hypercoagulability—elements of Virchow's triad. Bacteria and other microorganisms seeded from primary sites of infection reach the cavernous sinus via retrograde venous flow. Their presence within the sinus provokes endothelial activation, local inflammation, and the formation of platelet-fibrin thrombi that partially or completely occlude venous channels. The developing thrombus not only traps infection within the sinus but also impedes venous outflow from orbital and facial structures. As venous pressure rises, patients manifest periorbital and facial edema, chemosis, ptosis, proptosis, and pain with extraocular movements. Venous congestion in the retinal and cortical venous systems may lead to papilledema, retinal venous engorgement, and, in advanced cases, ischemic optic neuropathy and loss of vision.

The absence of valves within the dural venous system allows thrombus and infection to propagate freely along connected channels. The cavernous sinuses communicate with one another through anterior and posterior intercavernous sinuses that encircle the pituitary gland. Consequently, a process that begins unilaterally often becomes bilateral, explaining why clinical signs frequently evolve from unilateral to bilateral ophthalmoplegia and periorbital swelling. Thrombus may further extend into other dural sinuses and cortical veins, contributing to intracranial hypertension, venous infarction, and hemorrhagic transformation.[13] Local inflammation and mass effect within the cavernous sinus lead to progressive cranial neuropathies. The abducens nerve (VI), which traverses the sinus centrally adjacent to the internal carotid artery, is particularly vulnerable and is often the first cranial nerve affected. Patients typically present with horizontal diplopia and impaired lateral gaze due to abduction weakness. As inflammation intensifies, the oculomotor (III) and trochlear (IV) nerves may also be compromised, resulting in complete external ophthalmoplegia with inability to move the eye in any direction, ptosis, and misalignment of the globe. Internal ophthalmoplegia can occur through disruption of parasympathetic fibers carried by cranial nerve III, leading to a dilated, poorly reactive pupil, or through involvement of sympathetic fibers, producing miosis and features of a partial Horner syndrome.



Fig. 2: Pathophysiology and Inflammation during CVT.

Involvement of the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve produces sensory disturbances, including numbness, paresthesias, and pain in the distribution of the forehead, cornea, upper eyelid, nose, cheek, and upper jaw. Loss of the corneal reflex due to V1 dysfunction significantly increases the risk of corneal injury and keratitis. These cranial nerve deficits, particularly when combined with periorbital edema, chemosis, and fever, constitute a key clinical constellation for recognizing CST. Beyond local neurovascular compromise, septic CST can give rise to serious intracranial and systemic complications. Because the cavernous sinus communicates with the superior and inferior petrosal sinuses, transverse and sigmoid sinuses, and superficial cortical veins, infection can spread to produce meningitis, subdural empyema, or brain abscess. Venous hypertension and cortical vein thrombosis may lead to ischemic or hemorrhagic stroke, especially in regions where collateral drainage is limited. Involvement of the internal carotid artery within the sinus may result in vessel narrowing, vasculitis, or even carotid occlusion, further exacerbating ischemic risk. Systemically, septic emboli can disseminate via the jugular venous system into the pulmonary circulation, causing septic pulmonary emboli, lung abscesses, pneumonia, or pleural empyema. Involvement of the sellar region and pituitary vasculature may compromise pituitary blood supply, leading to hypopituitarism through ischemic necrosis or direct extension of infection into the pituitary gland. These endocrine disturbances may manifest as adrenal insufficiency, hypothyroidism, or gonadal failure, compounding the overall morbidity. Collectively, the pathophysiology of cavernous sinus thrombosis reflects the convergence of intricate anatomy, venous connectivity, infection, and thrombosis. The close relationship between the cavernous sinus, its draining territories, and critical neurovascular structures explains the rapid progression, multisystem involvement, and high potential for lasting disability, emphasizing the need for prompt recognition and aggressive management.[13]

History and Physical

Clinical History

The clinical presentation of cavernous sinus thrombosis (CST) is often subacute and polymorphic, requiring a high index of suspicion and careful history taking. Patients most frequently report systemic and focal symptoms that reflect both the underlying septic process and the evolving neuro-ophthalmic involvement. Fever is common and may precede localizing signs by hours to days, often accompanied by malaise, chills, and a general sense of illness. Headache is reported in approximately 50% to 90% of patients and is typically severe, deep, and retro-orbital or bifrontal in character. It may initially be unilateral and ipsilateral to the primary site of infection, later becoming diffuse or bilateral as inflammation and venous congestion extend across the intercavernous sinuses. The headache is often described as progressive and refractory to simple analgesics, occasionally associated with nausea, vomiting, or photophobia, which may lead clinicians to initially consider meningitis or migraine in the differential diagnosis. Local symptoms centered around the orbit and periorbital region are equally prominent. Patients commonly report periorbital swelling, redness, and ocular pain, often exacerbated by eye movements. Visual disturbances can include blurred vision, photophobia, diplopia, or more ominously, acute or progressive loss of vision. Diplopia usually reflects early involvement of the abducens nerve (cranial nerve VI) and manifests as horizontal double vision, particularly when looking toward the affected side. As the disease evolves, cranial neuropathies involving the oculomotor (III) and trochlear (IV) nerves may compound these symptoms, leading to complex ophthalmoplegia and further visual difficulty. Symptoms characteristically begin in one eye and, because of the venous and intercavernous connections, spread to involve the contralateral eye over hours to a few days, a temporal pattern that is highly suggestive of CST.

Less common but important systemic and neurological symptoms may include rigors, neck stiffness, and photophobia if meningeal irritation or meningitis develops. Facial numbness or paresthesias in the distribution of the ophthalmic (V1) or maxillary (V2) branches of the trigeminal nerve may be described as tingling, burning, or reduced sensation around the forehead, nose, cheek, or upper jaw. In more advanced or fulminant cases, patients may develop altered mental status, ranging from confusion and agitation to lethargy, obtundation, or coma, particularly when intracranial complications such as subdural empyema, brain abscess, or venous infarction occur. Seizures and focal stroke-like deficits, including hemiparesis or aphasia, are less common but represent severe disease with extension into cortical veins or adjacent brain parenchyma. A detailed history should also explore recent or concurrent facial, sinus, dental, or ear infections, recent surgery or trauma in the craniofacial region, immunosuppression, or prothrombotic conditions, as these frequently constitute the inciting or predisposing factors in CST [14].

Physical Examination Findings

The physical examination in CST often reveals a combination of systemic toxicity, focal neuro-ophthalmic signs, and occasionally meningeal or focal neurological deficits. Vital signs commonly demonstrate fever, which may be high and persistent in septic cases, along with tachycardia and, in severe sepsis, hypotension. A “picket fence” fever pattern, in which the temperature spikes abruptly and then returns to near normal only to rise again, has been described and is thought to correlate with intermittent bacteremia and involvement of the lateral wall of the cavernous sinus. This pattern, while not specific, should heighten suspicion when accompanied by localized orbital or facial signs. Ocular findings are nearly universal and present in up to 90% of patients, often providing the most striking and diagnostically useful clues. Periorbital edema is typically the earliest manifestation, beginning unilaterally and rapidly progressing to involve the contralateral side due to the intercavernous venous communications. The eyelids may appear swollen and erythematous, and chemosis—marked conjunctival edema—is frequently observed. Ptosis and proptosis result from venous congestion and impaired drainage of the orbital contents, producing forward displacement of the globe. Eye movements are usually restricted and often painful, reflecting both cranial nerve dysfunction and mechanical effects of increased orbital pressure. Visual function may be variably affected. Decreased visual acuity is reported in approximately 7% to 22% of cases, and fundoscopy may reveal papilledema, retinal venous engorgement, or hemorrhages, particularly as intracranial pressure rises or retinal venous outflow is impaired. Pupillary abnormalities are also encountered, including decreased pupillary light reflexes and, less frequently, visible conjunctival pulsations associated with arteriovenous hemodynamic changes. In severe or delayed cases, permanent blindness occurs in 8% to 15% of patients, often due to ischemic optic neuropathy or central retinal vein occlusion.

Cranial neuropathies are central to the physical diagnosis of CST. The sixth cranial nerve (abducens) is most commonly affected because of its medial position within the cavernous sinus, leading to partial ophthalmoplegia characterized by limited lateral gaze and horizontal diplopia. As the inflammatory and thrombotic process intensifies, involvement of the third and fourth cranial nerves leads to complete external ophthalmoplegia, with inability to move the eye in any direction, marked ptosis, and ophthalmic misalignment. Internal ophthalmoplegia manifests as a nonreactive pupil due to paralysis of the iris sphincter and ciliary muscles; this may appear as a constricted, nonreactive pupil when sympathetic fibers are disrupted, resulting in miosis, or as a dilated, nonreactive pupil when parasympathetic fibers from cranial nerve III are compromised, resulting in mydriasis [14]. Horner syndrome, characterized by ptosis, miosis, and facial anhidrosis, may also occur with disruption of sympathetic fibers in the carotid plexus. The sensory examination often reveals diminished facial sensation in the distribution of the ophthalmic (V1) and maxillary (V2) branches of the trigeminal nerve, with patients reporting numbness or tingling over the forehead, cornea, nose, and cheek. A decreased or absent corneal reflex is a particularly important sign, indicating V1 involvement and contributing to the risk of corneal ulceration. More generalized neurological findings, such as altered mentation, lethargy, or focal deficits, may point to complications like meningitis, venous infarction, or intracranial abscess formation. Together, these clinical features—when considered in the context of recent infection or prothrombotic risk—form the basis for prompt suspicion and early diagnostic evaluation of cavernous sinus thrombosis.

Evaluation

The evaluation of cavernous sinus thrombosis (CST) requires a high level of clinical suspicion, rapid diagnostic assessment, and prompt initiation of neuroimaging. Because the condition is rare and clinically overlaps with orbital cellulitis, meningitis, and stroke syndromes, establishing an accurate diagnosis relies on integrating detailed clinical examination with appropriate imaging and laboratory studies. Early confirmation is essential because delays in diagnosis correlate strongly with increased morbidity, including irreversible visual loss, cranial neuropathies, or intracranial complications.



Fig. 3: Diagnosis and Management of CVT.

Imaging Studies

Neuroimaging is the cornerstone of CST diagnosis, and contrast-enhanced studies provide the highest diagnostic yield. Contrast-enhanced computed tomography (CT) venography (CTV) and magnetic resonance venography (MRV) are considered highly sensitive and specific modalities, reliably detecting thrombosis, sinus enlargement, and associated orbital or intracranial pathology. In contrast, noncontrast imaging—such as plain CT or time-of-flight MRV—may overlook early or subtle findings, leading to underdiagnosis. Nevertheless, noncontrast CT is often the first study obtained in emergency settings, and although it is not ideal for definitively diagnosing CST, it can help identify abnormalities that raise suspicion. These subtle findings may include dilation or engorgement of the superior or inferior ophthalmic veins, exophthalmos due to impaired venous drainage, or convexity of the cavernous sinus margins. Additionally, CT may incidentally reveal underlying infectious sources such as sphenoid or ethmoid sinusitis, facial cellulitis, or masses near the sphenoid sinus or pituitary gland [15]. Contrast-enhanced MRI of the brain provides superior delineation of soft tissues and venous structures. Findings suggestive of CST include widening of the cavernous sinus, loss of the normal flow void on T2-weighted or gradient echo sequences, asymmetric enlargement compared with the contralateral side, and prominent dural enhancement. Postcontrast MRV or CTV can reveal heterogeneous filling defects, partial or complete absence of flow within the cavernous sinus, and abnormal convexity of the lateral sinus wall, which is typically concave on coronal imaging. These techniques are also valuable for visualizing complications such as thrombosis of the superior ophthalmic vein, enlargement of orbital fat, and impaired drainage of tributary veins. Major arterial involvement—such as narrowing or mural enhancement of the internal carotid artery—may also be seen, reflecting perivascular inflammation or vasculitis. Neuroimaging also plays a crucial role in identifying intracranial complications associated with CST. Cerebral infarctions can result from cortical vein thrombosis or carotid artery compression; intraparenchymal hemorrhage may also occur. Contrast studies may demonstrate subdural empyema, purulent meningitis, cerebritis, or discrete brain abscesses, underscoring the aggressive nature of septic CST. Because multiple venous thromboses are common, careful evaluation of all dural venous sinuses—including the transverse, sigmoid, straight sinus, and deep cerebral veins—is essential to avoid missing additional sites of thrombosis that may influence both prognosis and management [16][17][18][19][20].

Laboratory Studies

Laboratory testing provides supportive evidence for underlying infection, systemic inflammation, and coagulation abnormalities. Acute-phase reactants are frequently elevated, and most patients exhibit leukocytosis with elevated white blood cell (WBC) counts. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typically markedly increased, reflecting significant systemic inflammation. D-dimer levels may also be elevated due to ongoing thrombosis and fibrinolysis, although their absence does not exclude CST. Blood cultures should always be obtained prior to initiating antibiotics because they are often positive in septic CST and can identify the causative organism, guiding targeted therapy. Assessment for thrombophilic conditions can be considered but must be timed appropriately. Many assays—such as those evaluating protein C, protein S, or antithrombin III—may yield false results during acute infectious or thrombotic states, or when patients are receiving anticoagulation. Therefore, thrombophilia testing is typically deferred until after completion of acute treatment to ensure diagnostic accuracy. Lumbar puncture (LP) may be useful when meningitis is suspected or when distinguishing CST from other intracranial infections. Cerebrospinal fluid (CSF) may show elevated opening pressure due to impaired venous drainage, as well as pleocytosis, increased protein, or mildly reduced glucose. Importantly, CSF cultures may be negative even in cases of septic CST. As with any patient with suspected intracranial pathology, a lumbar puncture should only be performed after neuroimaging has excluded any mass effect or midline shift to prevent the risk of herniation. Overall, evaluation of CST requires a careful, coordinated diagnostic strategy integrating advanced neuroimaging, laboratory evidence, and clinical suspicion. Rapid recognition and thorough assessment significantly improve outcomes in this potentially fatal condition.

Treatment / Management

The management of cavernous sinus thrombosis (CST) is complex and requires rapid initiation of therapy due to the condition's aggressive clinical course and high risk of mortality and long-term neurological sequelae. Because CST is rare, evidence is largely derived from retrospective reviews, expert opinion, and extrapolation from cerebral venous and sinus thrombosis (CVST) literature rather than randomized controlled trials. Nonetheless, a consistent therapeutic principle has emerged: early, aggressive antimicrobial therapy combined with anticoagulation forms the cornerstone of treatment, often supplemented by supportive measures and surgical management of the primary source of infection when indicated [21].

Antimicrobial Therapy

Empiric broad-spectrum antimicrobial therapy should be initiated immediately upon suspicion of CST, even before culture results are available, to cover the wide array of potential bacterial and fungal pathogens. Septic CST is most frequently associated with *Staphylococcus aureus*, including methicillin-resistant strains, as well as streptococci, anaerobes, and gram-negative organisms. Therefore, an anti-staphylococcal agent—typically vancomycin when methicillin resistance is suspected—is recommended as first-line coverage. This is usually combined with a third-generation cephalosporin such as ceftriaxone or cefotaxime to provide broad-spectrum activity against streptococci and gram-negative bacteria. Metronidazole is added to ensure anaerobic coverage, particularly in cases originating from dental, sinus, or deep facial infections where anaerobes are prominent contributors. Fungal etiologies, though less common, are associated with extremely high morbidity and mortality and must be considered in immunocompromised patients, those with uncontrolled diabetes, or when imaging suggests angioinvasive disease. Amphotericin B is the recommended empiric antifungal agent, with dosing later tailored based on organism identification and patient response. Because septic CST reflects deep-seated infection within a venous sinus containing complex anatomical structures, prolonged parenteral therapy is necessary. A typical course involves 3 to 4 weeks of intravenous antibiotics or at least 2 weeks beyond complete clinical resolution. Even after discontinuation, patients require close follow-up to detect recurrence, persistent infection, or delayed complications.

Anticoagulation Therapy

The use of anticoagulation in CST remains a subject of ongoing debate. Despite the absence of randomized controlled trials, most experts support anticoagulation in the absence of strong contraindications because retrospective data suggest significant benefits. In historical analyses, unfractionated heparin (UFH) reduced mortality from approximately 40% to 14%, and the combination of anticoagulation with antibiotics reduced neurologic morbidity from 61% to 31%. Low molecular weight heparin (LMWH) is frequently preferred due to ease of administration and more predictable pharmacokinetics. The rationale for anticoagulation includes prevention of clot propagation, facilitation of venous recanalization, reduction of intracranial pressure, and potentially improved penetration of antimicrobial agents into infected tissues. Risks include systemic or intracranial hemorrhage and theoretical dissemination of septic emboli. However, data from the Cochrane Collaboration (Coutinho) on CVST indicate that anticoagulation is safe even in the presence of intracranial hemorrhage and may reduce mortality, although the evidence did not reach statistical significance. The European Federation of Neurological Societies (EFNS) recommends 3 months of anticoagulation for CVST associated with a transient risk factor, 6 to 12 months for idiopathic cases or mild thrombophilia, and indefinite treatment for recurrent thrombosis or severe thrombophilia. Given the similarities, many clinicians adopt similar durations for CST, though clear evidence is lacking. Thrombolysis remains inadequately supported and is not routinely recommended.

Corticosteroids

Corticosteroids are sometimes administered empirically despite limited evidence of efficacy in CST. The proposed benefit is reduction of inflammation, vasogenic edema, and compression of cranial nerves within the cavernous sinus, which may help relieve ophthalmoplegia. However, the International Study on Cerebral Veins and Dural Sinus Thrombosis (ISCVT) found no improvement with steroid therapy in CVST. Their use is therefore controversial and should not be routine. Steroids are, however, indicated when CST is complicated by hypopituitarism due to pituitary ischemia or glandular involvement.

Surgical Interventions

Direct surgical treatment of the cavernous sinus itself is contraindicated due to the high density of critical anatomical structures and the risk of catastrophic neurovascular injury. Instead, surgical management focuses on eradication of the primary source of infection or drainage of purulent collections. Procedures may include sphenoidectomy, ethmoidectomy, maxillary antrostomy, mastoidectomy, or drainage of dental or facial abscesses. Neurosurgical interventions such as craniotomy for subdural empyema or brain abscess, orbital decompression, or ventricular shunt placement may be required when complications arise. In cases involving angioinvasive fungal infections, particularly mucormycosis, extensive surgical debridement of necrotic sinus and orbital tissues is essential and may require repeated procedures. Overall, optimal treatment of CST demands an aggressive, multidisciplinary approach. Early initiation of broad-spectrum antimicrobial therapy, judicious anticoagulation, targeted surgical interventions, and vigilant supportive care significantly improve outcomes in this life-threatening condition.

Differential Diagnosis

The differential diagnosis of cavernous sinus thrombosis (CST) is broad and includes any condition that produces cavernous sinus syndrome or painful ophthalmoplegia. Because CST is rare but potentially fatal, clinicians must carefully distinguish it from other disorders that share overlapping clinical features, such as periorbital pain, cranial neuropathies, proptosis, and visual disturbance. Cavernous sinus syndrome can result from local compression of the cavernous sinus by noninfectious and nonthrombotic lesions, a substantial proportion of which are neoplastic. Approximately one-third of nonthrombotic cavernous sinus lesions are tumors, and these may include metastatic carcinomas, meningiomas, schwannomas, plexiform neurofibromas, pituitary adenomas, chordomas, chondrosarcomas, melanocytomas, cavernous hemangiomas, and nasopharyngeal carcinoma, the latter being a particularly important primary malignancy in some geographic regions. These tumors may produce progressive cranial nerve dysfunction rather than the more acute, septic picture characteristic of CST, but early manifestations can be similar. Vascular lesions such as carotid–cavernous fistulas form another important diagnostic consideration. These are characterized radiologically by proptosis, enlargement of the superior ophthalmic vein, engorged extraocular muscles, and a so-called “dirty” appearance of the retro-orbital fat on enhanced CT or MRI. Clinically, they often present with pulsatile exophthalmos, conjunctival arterialization, and bruit, features that help distinguish them from CST. Similarly, sino-orbital aspergillosis and other invasive fungal processes may mimic CST with painful ophthalmoplegia and orbital swelling, particularly in immunocompromised patients, but typically show mass-like sinus and orbital involvement on imaging.

Tolosa–Hunt syndrome, a granulomatous inflammatory pseudotumor involving the cavernous sinus and superior orbital fissure, is another critical mimic. Patients present with severe retro-orbital pain, ophthalmoplegia, and cranial nerve palsies, often closely resembling CST; however, systemic toxicity is usually absent, and symptoms characteristically respond dramatically to systemic corticosteroids. Superior orbital fissure syndrome and orbital apex syndrome, which involve inflammation or compression at the posterior orbit and fissure region, also produce ophthalmoplegia and sensory deficits of cranial nerves III, IV, V, and VI, with the orbital apex variant typically showing more profound visual loss and relatively less edema or proptosis than CST. A range of systemic inflammatory and infectious disorders can present with painful ophthalmoplegia and cranial neuropathies and must be considered in the differential diagnosis. These include orbital cellulitis, which is usually associated with prominent fever, leukocytosis, and localized sinus or eyelid infection; sarcoidosis with granulomatous orbital or meningeal involvement; and chronic infections such as syphilis and tuberculosis, which may affect the meninges, cranial nerves, or skull base. Distinguishing CST from these entities relies on a combination of clinical course, systemic features, imaging characteristics, and, when needed, laboratory and histopathologic evaluation. An integrated diagnostic approach is therefore essential to avoid misdiagnosis and delay in treating true cavernous sinus thrombosis.

Prognosis

The prognosis of cavernous sinus thrombosis has improved dramatically over the past decades, largely due to heightened clinical awareness, earlier recognition, and the availability of effective antimicrobial and supportive therapies. Historically, before the advent of antibiotics and modern neuroimaging, CST was almost uniformly fatal, with reported mortality rates approaching 80% to 100% in many early case series. With current standards of care—rapid initiation of broad-spectrum intravenous antibiotics, timely anticoagulation in appropriate patients, and management of the underlying source of infection—mortality has fallen substantially, with contemporary estimates in the range of approximately 8% to 13%.[22][23][24] This decline underscores the critical importance of early diagnosis, which depends on prompt recognition of characteristic presenting features such as fever, severe headache, periorbital swelling, and acute or subacute ophthalmoplegia involving cranial nerves III, IV, and VI. Despite these advances, CST remains associated with considerable long-term morbidity. Even with appropriate treatment, a significant proportion of survivors experience residual neurological deficits. Visual impairment, ranging from mild reduction in acuity to complete blindness, persists in up to one-fifth of patients, often as a consequence of ischemic optic neuropathy, central retinal vein occlusion, or chronic papilledema. Persistent cranial nerve palsies are even more common, with approximately 50% of patients having lasting deficits, most frequently involving cranial nerves III and VI.[22][24] These deficits may manifest as chronic diplopia, ptosis, restricted ocular motility, or facial sensory disturbances, all of which can significantly affect functional capacity and quality of life.

Prognosis is influenced by multiple factors, including the rapidity of diagnosis, the virulence of the underlying pathogen, the presence of comorbidities such as diabetes or immunosuppression, and the extent of intracranial complications at presentation. Patients who are present with advanced neurological involvement, such as coma, seizures, meningitis, brain abscess, or venous infarction, tend to have worse outcomes and higher mortality. Conversely, those identified early in the disease course, before irreversible optic nerve or brain injury occurs, have a better chance of full or near-full recovery. The presence of bilateral involvement, extensive venous sinus thrombosis, or associated carotid artery pathology may also portend a more complicated clinical trajectory. In addition, socioeconomic and healthcare system factors—such as delays in accessing care, limited availability of advanced imaging, or inadequate antimicrobial coverage—can significantly impact survival and functional outcomes. Long-term follow-up is therefore essential, not only to monitor late complications or recurrence but also to provide rehabilitative support, visual aids, and, when necessary, corrective strabismus or oculoplastic surgery to optimize functional recovery. In summary, while modern therapy has transformed CST from a nearly universally fatal condition to one with substantially improved survival, it continues to carry a high burden of disability. The prognosis is best when clinicians maintain a high index of suspicion, initiate early diagnostic imaging, and implement aggressive, multidisciplinary management tailored to the individual patient's clinical profile.[22][23][24]

Conclusion:

In conclusion, Cavernous Sinus Thrombosis (CST) remains a formidable medical emergency, though its prognosis has significantly improved with modern diagnostic and therapeutic advances. The key to a successful outcome lies in maintaining a high index of clinical suspicion, enabling early recognition of its characteristic signs—such as painful ophthalmoplegia, periorbital edema, and systemic toxicity—particularly in patients with preceding facial or sinus infections. Prompt confirmation with contrast-enhanced neuroimaging is essential to initiate timely treatment. The cornerstone of management is an aggressive, multimodal approach involving broad-spectrum intravenous antibiotics to target common pathogens like *Staphylococcus aureus*, coupled with anticoagulation to halt thrombus progression and mitigate complications. Surgical intervention is often required to eradicate the primary septic focus. Despite these measures, CST continues to be associated with substantial long-term morbidity, including persistent visual impairment and cranial nerve deficits, underscoring the severity of the condition. Therefore, a coordinated, interprofessional effort is critical to optimize acute care, manage complications, and provide necessary rehabilitation, ultimately improving survival and functional recovery for affected patients.

References:

1. Matthew TJH, Hussein A. Atypical Cavernous Sinus Thrombosis: A Diagnosis Challenge and Dilemma. Cureus. 2018 Dec 04;10(12):e3685.
2. Eltayeb AS, Karrar MA, Elbeshir EI. Orbital Subperiosteal Abscess Associated with Mandibular Wisdom Tooth Infection: A Case Report. J Maxillofac Oral Surg. 2019 Mar;18(1):30-33.
3. Dolapsakis C, Kranidioti E, Katsila S, Samarkos M. Cavernous sinus thrombosis due to ipsilateral sphenoid sinusitis. BMJ Case Rep. 2019 Jan 29;12(1)
4. Chen MC, Ho YH, Chong PN, Chen JH. A rare case of septic cavernous sinus thrombosis as a complication of sphenoid sinusitis. Tzu Chi Med J. 2019 Jan-Mar;31(1):63-65.
5. Kasha S, Bandari G. Bilateral Posterior Fracture-Dislocation of Shoulder Following Seizures Secondary to Cavernous Sinus Venous Thrombosis - A Rare Association. J Orthop Case Rep. 2018 Jul-Aug;8(4):49-52.
6. DiNubile MJ. Septic thrombosis of the cavernous sinuses. Arch Neurol. 1988 May;45(5):567-72.
7. Dinkin M, Patsalides A, Ertel M. Diagnosis and Management of Cerebral Venous Diseases in Neuro-Ophthalmology: Ongoing Controversies. Asia Pac J Ophthalmol (Phila). 2019 Jan-Feb;8(1):73-85.
8. Torretta S, Guastella C, Marchisio P, Marom T, Bosis S, Ibba T, Drago L, Pignataro L. Sinonasal-Related Orbital Infections in Children: A Clinical and Therapeutic Overview. J Clin Med. 2019 Jan 16;8(1)
9. Darmawan G, Hamijoyo L, Oehadian A, Bandiara R, Amalia L. Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus. Acta Med Indones. 2018 Oct;50(4):343-345.
10. Mulvey CL, Kiell EP, Rizzi MD, Buzi A. The Microbiology of Complicated Acute Sinusitis among Pediatric Patients: A Case Series. Otolaryngol Head Neck Surg. 2019 Apr;160(4):712-719.
11. Housley SB, McPheeters MJ, Raygor KP, Bouslama M, Scullen T, Davies JM. Cavernous Sinus Thrombosis. Neurosurg Clin N Am. 2024 Jul;35(3):305-310.
12. Weerasinghe D, Lueck CJ. Septic Cavernous Sinus Thrombosis: Case Report and Review of the Literature. Neuroophthalmology. 2016 Dec;40(6):263-276.
13. Neal TW, Schlieve T. Complications of Severe Odontogenic Infections: A Review. Biology (Basel). 2022 Dec 08;11(12)
14. Alam MS, Backiavathy V, Noronha V, Mukherjee B. Orbital abscess: 20 years' experience at a tertiary eye care center. Orbit. 2022 Dec;41(6):751-758.
15. Berge J, Louail C, Caillé JM. Cavernous sinus thrombosis diagnostic approach. J Neuroradiol. 1994 Apr;21(2):101-17.
16. Branson SV, McClintic E, Yeatts RP. Septic Cavernous Sinus Thrombosis Associated With Orbital Cellulitis: A Report of 6 Cases and Review of Literature. Ophthalmic Plast Reconstr Surg. 2019 May/Jun;35(3):272-280.
17. Deliran SS, Sondag L, Leijten QH, Tuladhar AM, Meijer FJA. [Headache: consider cavernous sinus thrombophlebitis]. Ned Tijdschr Geneeskd. 2018 Aug 16;162
18. Fujikawa T, Sogabe Y. Septic cavernous sinus thrombosis: potentially fatal conjunctival hyperemia. Intensive Care Med. 2019 May;45(5):692-693.
19. van der Poel NA, de Witt KD, van den Berg R, de Win MM, Mourits MP. Impact of superior ophthalmic vein thrombosis: a case series and literature review. Orbit. 2019 Jun;38(3):226-232.
20. Leach JL, Fortuna RB, Jones BV, Gaskill-Shipley MF. Imaging of cerebral venous thrombosis: current techniques, spectrum of findings, and diagnostic pitfalls. Radiographics. 2006 Oct;26 Suppl 1:S19-41; discussion S42-3.
21. Akarapas C, Wiwatkunupakarn N, Sithirungson S, Chaiyasate S. Anticoagulation for cavernous sinus thrombosis: a systematic review and individual patient data meta-analysis. Eur Arch Otorhinolaryngol. 2025 Mar;282(3):1127-1134.
22. Wang YH, Chen PY, Ting PJ, Huang FL. A review of eight cases of cavernous sinus thrombosis secondary to sphenoid sinusitis, including a12-year-old girl at the present department. Infect Dis (Lond). 2017 Sep;49(9):641-646.
23. Frank GS, Smith JM, Davies BW, Mirsky DM, Hink EM, Durairaj VD. Ophthalmic manifestations and outcomes after cavernous sinus thrombosis in children. J AAPOS. 2015 Aug;19(4):358-62.
24. Caranfa JT, Yoon MK. Septic cavernous sinus thrombosis: A review. Surv

Ophthalmol. 2021 Nov-Dec;66(6):1021-1030